1. Dysregulation in Akt/mTOR/HIF-1 signaling identified by proteo-transcriptomics of SARS-CoV-2 infected cells.
- Author
-
Appelberg S, Gupta S, Svensson Akusjärvi S, Ambikan AT, Mikaeloff F, Saccon E, Végvári Á, Benfeitas R, Sperk M, Ståhlberg M, Krishnan S, Singh K, Penninger JM, Mirazimi A, and Neogi U
- Subjects
- COVID-19, Cell Line, Chromatography, Liquid, Coronavirus Infections genetics, Coronavirus Infections metabolism, Gene Expression Regulation, High-Throughput Nucleotide Sequencing, Humans, Hypoxia-Inducible Factor 1 genetics, Hypoxia-Inducible Factor 1 metabolism, Pandemics, Pneumonia, Viral genetics, Pneumonia, Viral metabolism, Proto-Oncogene Proteins c-akt genetics, Proto-Oncogene Proteins c-akt metabolism, SARS-CoV-2, TOR Serine-Threonine Kinases genetics, TOR Serine-Threonine Kinases metabolism, Tandem Mass Spectrometry, Betacoronavirus pathogenicity, Coronavirus Infections virology, Gene Expression Profiling methods, Pneumonia, Viral virology, Proteomics methods, Signal Transduction
- Abstract
How severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections engage cellular host pathways and innate immunity in infected cells remains largely elusive. We performed an integrative proteo-transcriptomics analysis in SARS-CoV-2 infected Huh7 cells to map the cellular response to the invading virus over time. We identified four pathways, ErbB, HIF-1, mTOR and TNF signaling, among others that were markedly modulated during the course of the SARS-CoV-2 infection in vitro . Western blot validation of the downstream effector molecules of these pathways revealed a dose-dependent activation of Akt, mTOR, S6K1 and 4E-BP1 at 24 hours post infection (hpi). However, we found a significant inhibition of HIF-1α through 24hpi and 48hpi of the infection, suggesting a crosstalk between the SARS-CoV-2 and the Akt/mTOR/HIF-1 signaling pathways. Inhibition of the mTOR signaling pathway using Akt inhibitor MK-2206 showed a significant reduction in virus production. Further investigations are required to better understand the molecular sequelae in order to guide potential therapy in the management of severe coronavirus disease 2019 (COVID-19) patients.
- Published
- 2020
- Full Text
- View/download PDF